Amplia Therapeutics logo

ATX - Amplia Therapeutics Share Price

A$0.29 0.0  0.0%

Last Trade - 5:10am

Micro Cap
Market Cap £17.7m
Enterprise Value £15.5m
Revenue £19.4k
Position in Universe 1256th / 1844
Unlock ATX Revenue
Relative Strength (%)
1m +24.1%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -21.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.030 2.29 1.83 0.64 0.050 0.034 +2.5%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 September 2020, AmpliaTherapeutics Ltd revenues was not reported. Net lossdecreased 42% to A$511K. Lower net loss reflects Patent andassociated expenses decrease of 9% to A$6K (expense),Depreciation remaining flat at A$0K. Basic Earnings perShare excluding Extraordinary Items increased from -A$0.02to -A$0.01.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ATX Revenue Unlock ATX Revenue

Net Income

ATX Net Income Unlock ATX Revenue

Normalised EPS

ATX Normalised EPS Unlock ATX Revenue

PE Ratio Range

ATX PE Ratio Range Unlock ATX Revenue

Dividend Yield Range

ATX Dividend Yield Range Unlock ATX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ATX EPS Forecasts Unlock ATX Revenue
Profile Summary

Amplia Therapeutics Limited, formerly Innate Immunotherapeutics Limited, is a pharmaceutical company. The Company is engaged in research and development of immune-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumors. The Company is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly focused on pancreatic and ovarian cancer. Its initial clinical development pipeline comprises of two novel orally available small molecule FAK inhibitors: AMP945 (FAK-only) and AMP886 (FAK/FLT3/VEGFR3).

Last Annual March 31st, 2020
Last Interim September 30th, 2020
Incorporated October 11, 2013
Public Since December 23, 2013
No. of Shareholders: n/a
No. of Employees: 1
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 107,441,000
Free Float (0.0%)
Eligible for
ATX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ATX
Upcoming Events for ATX
Frequently Asked Questions for Amplia Therapeutics
What is the Amplia Therapeutics share price?

As of 5:10am, shares in Amplia Therapeutics are trading at A$0.29, giving the company a market capitalisation of £17.7m. This share price information is delayed by 15 minutes.

How has the Amplia Therapeutics share price performed this year?

Shares in Amplia Therapeutics are currently trading at A$0.29 and the price has moved by 0.335k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Amplia Therapeutics price has moved by 0.344k% over the past year.

What are the analyst and broker recommendations for Amplia Therapeutics?

There are no analysts currently covering Amplia Therapeutics.

When will Amplia Therapeutics next release its financial results?

Amplia Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Amplia Therapeutics dividend yield?

Amplia Therapeutics does not currently pay a dividend.

Does Amplia Therapeutics pay a dividend?

Amplia Therapeutics does not currently pay a dividend.

When does Amplia Therapeutics next pay dividends?

Amplia Therapeutics does not currently pay a dividend.

How do I buy Amplia Therapeutics shares?

To buy shares in Amplia Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Amplia Therapeutics?

Shares in Amplia Therapeutics are currently trading at A$0.29, giving the company a market capitalisation of £17.7m.

Where are Amplia Therapeutics shares listed? Where are Amplia Therapeutics shares listed?

Here are the trading details for Amplia Therapeutics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: ATX
What kind of share is Amplia Therapeutics?

Based on an overall assessment of its quality, value and momentum, Amplia Therapeutics is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Amplia Therapeutics share price forecast 2021?

We were not able to load any forecast data for Amplia Therapeutics.

How can I tell whether the Amplia Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amplia Therapeutics. Over the past six months, the relative strength of its shares against the market has been 62.42%. At the current price of A$0.29, shares in Amplia Therapeutics are trading at 77.15% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Amplia Therapeutics PE Ratio?

We were not able to find PE ratio data for Amplia Therapeutics.

Who are the key directors of Amplia Therapeutics?

Amplia Therapeutics's management team is headed by:

Jeff Carter - CFO
Margaret Rhoades - OTH
Ken Tucker - OTH
Andrew Cooke - SEC
Janette Dixon - VBD
Robert Peach - NED
Warwick Tong - CHM
Christopher Burns - DRC
John Lambert - CEO
Mark Devlin - CSO
Who are the major shareholders of Amplia Therapeutics?

Here are the top five shareholders of Amplia Therapeutics based on the size of their shareholding:

Platinum Investment Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 15.94% (17.2m shares)
Blueflag Holdings Pty. Ltd. Corporation
Percentage owned: 6.96% (7.50m shares)
CTxT Pty. Ltd. Corporation
Percentage owned: 4.19% (4.51m shares)
Collins (Mary) Individual Investor
Percentage owned: 3.09% (3.33m shares)
Elk River Holdings Pty. Ltd. Corporation
Percentage owned: 2.73% (2.94m shares)
Similar to ATX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.